FDA approves generic version of GoLytely
PITTSBURGH The Food and Drug Administration has approved a generic version of a prescription laxative made by Mylan, the generic drug company announced Friday.
The FDA approved Mylan’s polyethylene glycol 3350 and electrolytes for oral solution, a generic version of Braintree Labs’ GoLytely.
Branded and generic versions of the drug had sales of $14 million during the 12-month period ended Sept. 30, according to IMS Health.
Good Neighbor Pharmacy, InSite extranet wins Best in Class award
VALLEY FORGE, Pa. Drug wholesaler and health services giant AmerisourceBergen and its Good Neighbor Pharmacy retail division have been tapped for a “best in class award” for their effort to improve business practices through advanced technology.
The award came at the MicroStrategy World 2010 conference Wednesday. GNP’s InSite system was honored as a cutting-edge extranet application for pharmacy owners.
The InSite system, powered by MicroStrategy, is a business intelligence application developed for retail pharmacies. Within the system are dashboards that provide analytics and personalized information to help pharmacy owners –– including those that own and operate the more than 3,500 GNP locations nationwide –– make better business decisions.
“The management team and our Good Neighbor Pharmacy customers have worked diligently on developing this extranet site which will allow pharmacy owners to uncover opportunities to expand their business, reduce unnecessary costs, help with reimbursement strategies and identify and attract patients with critical needs,” said Chuck Reed, group VP for business management in AmerisourceBergen’s retail sales and marketing unit.
The InSite system also allows customers to compare their performance against peer-group pharmacies, and improve their interactions with patients.
“This is the Web site that allows the retail pharmacist to track their prescription fills, see how they fare against other pharmacies of similar size and markets, and see where they need to improve or are making progress against several key performance indicators,” explained ABC spokesperson Nora Beger.
Teva UK launches generic eye treatment
CASTLEFORD, England The British subsidiary of Teva Pharmaceutical Industries has launched a treatment for intra-ocular pressure resulting from ocular hypertension, open-angle glaucoma and pseudo-exfoliative glaucoma, the generic drug maker announced Thursday.
Teva UK launched dorzolamide eye drops in the 2% strength, which is meant for use as an adjunctive therapy to beta blockers or for patients who have not responded to treatment with beta blockers.
The drug is a generic version of Trusopt, made by MSD in the United Kingdom and Merck & Co. in the United States.